These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 7386484)
1. FDA commissioner discusses issues of concern to hospital pharmacists. Interview by William A. Zellmer. Goyan JE Am J Hosp Pharm; 1980 May; 37(5):738-40 contd. PubMed ID: 7386484 [No Abstract] [Full Text] [Related]
2. An interview with FDA commissioner Hayes. Small WE Am Pharm; 1981 Oct; NS21(10):27-36. PubMed ID: 6803557 [No Abstract] [Full Text] [Related]
3. FDA acts on estrogen, progestin labeling. FDA Consum; 1977 Nov; 11(9):3. PubMed ID: 10305006 [No Abstract] [Full Text] [Related]
4. An interview with FDA Commissioner Frank Young. Interview by Carmella Bocchino. Young FE Nurs Econ; 1989; 7(5):242-8. PubMed ID: 2812067 [TBL] [Abstract][Full Text] [Related]
5. Mandatory PPIs to begin in 1981; APhA issues strong objections. Small WE Am Pharm; 1980 Nov; NS20(11):10-1. PubMed ID: 7457342 [No Abstract] [Full Text] [Related]
6. Current FDA directives for promoting public health. Hayes AH Am J Hosp Pharm; 1982 Mar; 39(3):427-31. PubMed ID: 7072727 [TBL] [Abstract][Full Text] [Related]
7. Sounding board. Creative tension: FDA and medicine. Kennedy D N Engl J Med; 1978 Apr; 298(15):846-50. PubMed ID: 345121 [No Abstract] [Full Text] [Related]
9. The legal status of patient package inserts. Whitman JA Hosp Formul; 1978 Oct; 13(10):789-91. PubMed ID: 10238809 [No Abstract] [Full Text] [Related]
10. A means to provide patient education: "Rx package inserts, patient package inserts, device labeling". Sherman M ONA J; 1979 Aug; 6(8):326-9. PubMed ID: 257297 [No Abstract] [Full Text] [Related]
11. FDA in hot water again over cost of proposed drug labeling rule. Demkovich LE Natl J (Wash); 1979 Sep; 11(38):1568-70. PubMed ID: 10243426 [No Abstract] [Full Text] [Related]
13. A conversation with Commissioner Jere E. Goyan, pharmacist. Interview by William E. Small. Goyan JE Am Pharm; 1980 Jan; NS20(1):19-24. PubMed ID: 7378168 [No Abstract] [Full Text] [Related]
14. The process of drug decision making: perspectives of an FDA Commissioner. Hayes AH Hosp Formul; 1985 Aug; 20(8):896-900. PubMed ID: 10272396 [TBL] [Abstract][Full Text] [Related]
15. The meaning of FDA approval. Fischer RG Pediatr Nurs; 1987; 13(5):360. PubMed ID: 3658520 [No Abstract] [Full Text] [Related]
16. Did FDA jump the gun? Archambault GF Hosp Formul; 1977 Oct; 12(10):722. PubMed ID: 10305387 [No Abstract] [Full Text] [Related]
17. Content and format for labeling for human prescription drugs; amendment of effective date for certain biological products--Food and Drug Administration. Final rule. Fed Regist; 1981 Jan; 46(15 pt 1):7271-3. PubMed ID: 10249526 [TBL] [Abstract][Full Text] [Related]